FDA Removes Risk Evaluation Management Strategies (REMS) for ESAs
Apr 13
2017
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategy (REMS) requirements for the use of Epogen/Procrit and Aranesp to treat patients with anemia due to associated myelosuppressive chemotherapy.